CMI Communications is ESCMID’s first official fully open-access journal creating an interdisciplinary forum for knowledge exchange on translational and clinical aspects of infectious diseases and their prevention and control, microbiology, and related immunology, epidemiology, and public health. Readers can expect to find reviews and original articles providing knowledge and evidence to continually improve their healthcare practice, research, and policies.
What are WHO's most wanted bacterial pathogens in 2024? Hosts Angela Huttner & Oana Sandulescu welcome guests Dr. Hatim Sati of the World Health Organisation (WHO) and Dr. Erin Duffy (CARB-X) to discuss WHO’s new Priority Pathogens List. Developed by WHO and a panel of global experts, the List identifies the ‘top’ bacteria for which research & development are of critical, high, and medium priority, and thus serves as a framework for resource allocation and public-policy guidance. Episode peer-reviewed by Dr. Galadriel Pellejero of Lozano Blesa Clinical Hospital, Zaragoza, Spain.
Literature:
WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance.
https://www.who.int/publications/i/item/9789240093461
The new journal will publish articles that are of practical use to infectious disease clinicians and clinical microbiologists — and thus to their patients. We particularly want to help early-career professionals broaden their skills, knowledge, and career opportunities. This means we must meet them where they are. First submissions will have almost no formatting requirements and turnaround times will be short. CMI Com will host a regular podcast, and its website will include interactive features allowing debate, knowledge transfer, and other exchanges. The new journal should be thought of as a living platform — a sort of workbench, an endoplasmic reticulum where many little ribosomes can get together to build good things — and not as a bundle of papers arriving once a month in the mail.
We are currently hosting an open call for papers outlined below.
What are WHO's most wanted bacterial pathogens in 2024? Hosts Angela Huttner & Oana Sandulescu welcome guests Dr. Hatim Sati of the World Health Organisation (WHO) and Dr. Erin Duffy (CARB-X) to discuss WHO’s new Priority Pathogens List. Developed by WHO and a panel of global experts, the List identifies the ‘top’ bacteria for which research & development are of critical, high, and medium priority, and thus serves as a framework for resource allocation and public-policy guidance. Episode peer-reviewed by Dr. Galadriel Pellejero of Lozano Blesa Clinical Hospital, Zaragoza, Spain.
Literature:
WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance.
https://www.who.int/publications/i/item/9789240093461
Listen on your favourite channel
In this episode, hosts Josh Davis (Newcastle, Australia) and Angela Huttner (Geneva, Switzerland) interview the phage ‘microbiologist-clinician duo’, Drs. Shawna McCallin and Lorenz Leitner (Balgrist Hospital, Zurich, Switzerland). They explore the history of phages, the process of bringing phage therapy to a patient, potential resistance to phages, availability of individualized therapy versus phage cocktails, and the place of phage therapy in the future. Drs. Leitner and McCallin reflect on the challenges and lessons of their recently published randomized trial comparing phage therapy to antibiotics for urinary tract infection. Episode peer-reviewed by Dr. Olivia Funk of Long Island University.
Literature:
Leitner L, Ujmajuridze A, Chanishvili N et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021 Mar;21(3):427-436. doi: 10.1016/S1473-3099(20)30330-3.
Listen on your favourite channel
CMI Communications editors Angela Huttner, Marc Bonten, and Erin McCreary discuss late-breaker clinical trials presented at ESCMID Global (ECCMID) in Barcelona, providing insights into the trials’ designs, results, and implications. The DOTS trial compared two doses of long-acting dalbavancin to standard of care in patients with complicated S. aureus bacteremia. GAME-CHANGER compared cefiderocol to standard of care for gram-negative infections. PediCAP compared oral step-down therapy with amoxicillin with or without clavulanic acid at shorter durations to the current WHO-recommended standard of five days of intravenous antibiotic therapy in children with severe pneumonia. Additional results from the MULTICAP and CLEEN trials, the CAMERA-2 follow-on in vitro analysis, and the Burkina Faso Escherichia coli transmission study are also discussed. Episode peer-reviewed by Dr. Yousra Kherabi.
Listen on your favourite channel